Studies
| Study First Submitted Date | 2020-05-01 |
| Study First Posted Date | 2020-05-07 |
| Last Update Posted Date | 2021-03-01 |
| Verification Month Year | February 2021 |
| Verification Date | 2021-02-28 |
| Last Update Posted Date | 2021-03-01 |
Facilities
| Sequence: | 198416610 |
| Name | University of California, San Francisco |
| City | San Francisco |
| State | California |
| Zip | 94143 |
| Country | United States |
Conditions
| Sequence: | 51730101 | Sequence: | 51730102 | Sequence: | 51730103 |
| Name | Prostate Cancer | Name | Prostate | Name | Prostate Adenocarcinoma |
| Downcase Name | prostate cancer | Downcase Name | prostate | Downcase Name | prostate adenocarcinoma |
Id Information
| Sequence: | 39807877 | Sequence: | 39807878 |
| Id Source | org_study_id | Id Source | secondary_id |
| Id Value | EA-HOPE20200129 | Id Value | 20-30046 |
| Id Type | Other Identifier | ||
| Id Type Description | University of California, San Francisco | ||
Countries
| Sequence: | 42207025 |
| Name | United States |
| Removed | False |
Interventions
| Sequence: | 52051792 | Sequence: | 52051793 |
| Intervention Type | Drug | Intervention Type | Procedure |
| Name | 68Gallium-PSMA-11 | Name | Positron Emission Tomography (PET) |
| Description | PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). | Description | A PET scan is an imaging test that helps reveal how your tissues and organs are functioning using a radioactive drug (tracer) to show this activity |
Browse Conditions
| Sequence: | 191712273 | Sequence: | 191712274 | Sequence: | 191712275 | Sequence: | 191712276 | Sequence: | 191712277 | Sequence: | 191712278 | Sequence: | 191712279 | Sequence: | 191712280 | Sequence: | 191712281 | Sequence: | 191712282 |
| Mesh Term | Prostatic Neoplasms | Mesh Term | Genital Neoplasms, Male | Mesh Term | Urogenital Neoplasms | Mesh Term | Neoplasms by Site | Mesh Term | Neoplasms | Mesh Term | Genital Diseases, Male | Mesh Term | Genital Diseases | Mesh Term | Urogenital Diseases | Mesh Term | Prostatic Diseases | Mesh Term | Male Urogenital Diseases |
| Downcase Mesh Term | prostatic neoplasms | Downcase Mesh Term | genital neoplasms, male | Downcase Mesh Term | urogenital neoplasms | Downcase Mesh Term | neoplasms by site | Downcase Mesh Term | neoplasms | Downcase Mesh Term | genital diseases, male | Downcase Mesh Term | genital diseases | Downcase Mesh Term | urogenital diseases | Downcase Mesh Term | prostatic diseases | Downcase Mesh Term | male urogenital diseases |
| Mesh Type | mesh-list | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor |
Sponsors
| Sequence: | 47909688 |
| Agency Class | OTHER |
| Lead Or Collaborator | lead |
| Name | University of California, San Francisco |
Overall Officials
| Sequence: | 29028567 |
| Role | Principal Investigator |
| Name | Thomas Hope, MD |
| Affiliation | University of California, San Francisco |
Eligibilities
| Sequence: | 30508238 |
| Gender | Male |
| Minimum Age | 18 Years |
| Maximum Age | N/A |
| Criteria | Biochemical recurrent and pre-prostatectomy staging participants will be eligible and must meet the following criteria: Inclusion Criteria: Age ≥ 18 years Histopathologically confirmed or biopsy proven prostate adenocarcinoma. Concern for metastatic disease in one of the following settings: Initial staging with intermediate to high risk prostate cancer. Biochemical recurrence after initial therapy. Ability to understand a written informed consent document, and the willingness to sign it Exclusion Criteria: 1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation |
| Adult | True |
| Child | False |
| Older Adult | True |
Calculated Values
| Sequence: | 254055813 |
| Number Of Facilities | 1 |
| Registered In Calendar Year | 2020 |
| Were Results Reported | False |
| Has Us Facility | True |
| Has Single Facility | True |
| Minimum Age Num | 18 |
| Minimum Age Unit | Years |
Intervention Other Names
| Sequence: | 26458266 | Sequence: | 26458267 | Sequence: | 26458268 |
| Intervention Id | 52051792 | Intervention Id | 52051793 | Intervention Id | 52051793 |
| Name | PSMA-HBED-CC | Name | PET | Name | PET Scan |
Responsible Parties
| Sequence: | 28637814 |
| Responsible Party Type | Principal Investigator |
| Name | Thomas Hope |
| Title | Principal Investigator |
| Affiliation | University of California, San Francisco |